eCancerMedicalScience

Scope & Guideline

Connecting minds to conquer cancer.

Introduction

Immerse yourself in the scholarly insights of eCancerMedicalScience with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageItalian
ISSN1754-6605
PublishereCancer Global Foundation
Support Open AccessYes
CountryUnited Kingdom
TypeJournal
Converge2007, from 2009 to 2024
AbbreviationECANCERMEDICALSCIENC / eCancerMedicalScience
Frequency-
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address13 King Square Avenue, Bristol BS2 8HU, UNITED KINGDOM

Aims and Scopes

The journal 'eCancerMedicalScience' aims to advance knowledge in the field of oncology through a diverse range of research articles that focus on cancer epidemiology, treatment strategies, and healthcare delivery, particularly in low- and middle-income countries. The journal emphasizes the importance of addressing the unique challenges faced in these regions while promoting innovative solutions and collaborations across disciplines.
  1. Cancer Epidemiology and Public Health:
    The journal covers studies that analyze cancer incidence, prevalence, and mortality rates, particularly in underrepresented populations, thereby contributing to a more comprehensive understanding of cancer's impact globally.
  2. Innovative Treatment Modalities:
    Research articles focus on novel therapies, including immunotherapy, targeted treatments, and combination therapies, highlighting their effectiveness in diverse patient populations and addressing disparities in access to care.
  3. Healthcare Systems and Policy:
    The journal explores the intersection of cancer care and health policy, examining how healthcare systems can be optimized to improve access, quality, and equity in cancer treatment, especially in resource-limited settings.
  4. Patient-Centered Care and Survivorship:
    The scope includes studies on quality of life, psychosocial aspects of cancer care, and survivorship issues, emphasizing the importance of holistic approaches to cancer treatment.
  5. Educational and Training Initiatives:
    The journal promotes articles that assess and enhance oncology education and training for healthcare professionals, particularly in low-resource environments, to improve cancer management and outcomes.
The journal has identified several emerging themes in recent publications that reflect the evolving landscape of cancer research and treatment, particularly in response to global health challenges and advancements in technology.
  1. Telemedicine and Digital Health Solutions:
    The rise of telemedicine, especially during the COVID-19 pandemic, has led to increased research on its implementation in oncology, highlighting its potential to improve access to care and patient outcomes.
  2. Health Disparities and Access to Care:
    There is a growing focus on understanding and addressing disparities in cancer care, particularly in low- and middle-income countries, emphasizing the need for equitable healthcare solutions.
  3. Immunotherapy and Personalized Medicine:
    An increasing number of studies are dedicated to exploring immunotherapy and personalized treatment plans, reflecting a shift towards more effective and individualized cancer treatments.
  4. Survivorship and Quality of Life Research:
    Research on survivorship issues, including long-term effects of cancer treatment and quality of life assessments, is gaining traction, emphasizing the importance of holistic care for cancer survivors.
  5. Interdisciplinary Approaches in Cancer Care:
    Emerging themes include the integration of different specialties in cancer treatment, such as combining surgical, medical, and supportive care, to enhance patient outcomes and streamline treatment pathways.

Declining or Waning

While 'eCancerMedicalScience' has consistently focused on various aspects of oncology, certain themes have shown a decline in prominence over recent years. This may reflect shifting priorities in cancer research or changes in the global healthcare landscape.
  1. Traditional Chemotherapy Approaches:
    There has been a noticeable decrease in publications focusing solely on conventional chemotherapy regimens, as research increasingly shifts towards personalized medicine and targeted therapies that offer more effective treatment options.
  2. General Cancer Awareness Campaigns:
    While still relevant, the frequency of articles solely dedicated to general cancer awareness initiatives has decreased, possibly due to a growing emphasis on specific interventions and evidence-based strategies tailored to particular populations.
  3. Palliative Care Focused Studies:
    Although palliative care remains crucial, there has been a waning interest in studies that do not integrate palliative approaches with oncological treatments, suggesting a trend towards more comprehensive care models.
  4. Single-Institution Studies:
    Research focusing exclusively on single-institution experiences is becoming less common, as collaborative and multi-centre studies gain traction, reflecting a desire for broader applicability and generalizability of findings.
  5. Basic Science and Laboratory Research:
    There appears to be a decline in studies rooted in basic science related to oncology, as clinical applications and translational research take precedence in addressing urgent clinical needs.

Similar Journals

BREAST CANCER RESEARCH AND TREATMENT

Driving Change through Cutting-Edge Studies
Publisher: SPRINGERISSN: 0167-6806Frequency: 18 issues/year

Breast Cancer Research and Treatment, published by Springer, stands as a pivotal journal within the domains of Cancer Research and Oncology, exemplified by its impressive Q2 and Q1 quartile rankings, respectively, in the 2023 category rankings. Since its inception in 1981, this journal has provided a vital platform for disseminating cutting-edge research focused on all aspects of breast cancer, ranging from molecular biology to treatment strategies. With an ISSN of 0167-6806 and E-ISSN of 1573-7217, it captures a broad audience of researchers, clinicians, and students dedicated to improving patient outcomes. The journal emphasizes high-quality, peer-reviewed studies that pave the way for advancements in therapy and direct novel insights into oncological practices. By maintaining a strong ranking in Scopus with percentile placements of 74th in Oncology and 61st in Cancer Research, Brest Cancer Research and Treatment continues to foster innovation and collaboration in the fight against breast cancer.

Clinical Lymphoma Myeloma & Leukemia

Fostering Collaboration in Blood Cancer Science
Publisher: CIG MEDIA GROUP, LPISSN: 2152-2650Frequency: 6 issues/year

Clinical Lymphoma Myeloma & Leukemia is a prestigious journal dedicated to the study and treatment of hematologic malignancies, offering a vital platform for researchers and healthcare professionals in the fields of oncology, hematology, and cancer research. Published by CIG MEDIA GROUP, LP, this journal has established itself as a crucial resource since its inception in 2010, with a continuous commitment to disseminating knowledge until at least 2024. With an impact factor that objectively reflects its influence, it is rated in Q3 quartiles in both Cancer Research and Hematology as well as in Oncology as of 2023. Researchers can access a wealth of articles and studies that explore various dimensions of lymphoma, myeloma, and leukemia, thus fostering an environment of collaboration and innovation. Although it currently does not offer full open access, its extensive archive and rigorous peer-review process ensure the publication of high-quality research, making it an essential resource for anyone dedicated to advancing the science and practice of treating blood cancers.

INTERNATIONAL JOURNAL OF CANCER

Exploring the frontiers of cancer science and treatment.
Publisher: WILEYISSN: 0020-7136Frequency: 24 issues/year

INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.

World Journal of Gastrointestinal Oncology

Illuminating the complexities of gastrointestinal cancer research.
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 1948-5204Frequency: 12 issues/year

World Journal of Gastrointestinal Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a pivotal resource in the evolving fields of gastroenterology and oncology, particularly focused on the intricate relationship between gastrointestinal disorders and cancer. Established in 2014, the journal continues to publish influential research, boasting a commendable Q2 ranking in both the gastroenterology and oncology categories for 2023, which underscores its importance in these critical medical domains. With a diverse range of topics and studies, it serves as an essential platform for researchers, healthcare professionals, and students aiming to stay informed about the latest advancements and innovations in gastrointestinal oncology. Though currently not classified as open access, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to clinical practice and patient care. Its positioning in the Scopus rankings also highlights its competitive standing within the scientific community, fostering discussions that are crucial for advancing both fields. Explore the latest insights and findings to enhance your understanding and contribute to the ongoing dialogue in gastrointestinal health and oncology.

Cancers

Unleashing insights to combat cancer effectively.
Publisher: MDPIISSN: Frequency: 24 issues/year

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

Cancer Reports

Connecting researchers and clinicians for impactful change.
Publisher: WILEYISSN: Frequency: 12 issues/year

Cancer Reports, published by WILEY, is an esteemed open-access journal dedicated to the field of oncology and cancer research. With a focus on disseminating impactful research findings since its transition to fully open access in 2021, Cancer Reports aims to facilitate knowledge sharing among researchers, clinicians, and healthcare professionals globally. The journal is positioned within the Q3 quartile for both Cancer Research and Oncology categories as of 2023, reflecting its commitment to quality and relevance in a competitive publishing landscape. With an ISSN of N/A and an E-ISSN of 2573-8348, the journal showcases studies across diverse aspects of cancer biology, treatment modalities, and patient care strategies. Located in the United Kingdom at 111 River St, Hoboken 07030-5774, NJ, Cancer Reports strives to contribute to the advancement of cancer research and improve health outcomes for patients worldwide, making it a pivotal platform for scholars and practitioners in the oncology community.

ONCOLOGY-NEW YORK

Delivering the Latest Breakthroughs in Cancer Science.
Publisher: UBM MEDICAISSN: 0890-9091Frequency: 12 issues/year

ONCOLOGY-NEW YORK is a prominent journal dedicated to the field of oncology, published by UBM MEDICA. Since its inception in 1987, the journal has served as a pivotal platform for disseminating groundbreaking research and advancements in cancer treatment, research, and education. With an ISSN of 0890-9091 and an E-ISSN of 2767-7389, it stands as an accessible resource for professionals, researchers, and students alike. The journal currently holds impressive rankings, categorized within Q3 in Oncology and Q4 in Cancer Research for 2023, reflecting its commitment to high-quality research output and contributions to the field. Despite its challenges in Scopus rankings, positioned at #283/404 in Medicine: Oncology and #188/230 in Biochemistry, Genetics, and Molecular Biology: Cancer Research, ONCOLOGY-NEW YORK continues to primarily focus on innovative cancer therapies and emerging clinical research. The journal's ongoing dedication to enhancing knowledge and understanding in oncology makes it a vital resource for all stakeholders invested in combating cancer.

CANCER TREATMENT REVIEWS

Navigating the complexities of cancer treatment advancements.
Publisher: ELSEVIER SCI LTDISSN: 0305-7372Frequency: 10 issues/year

Cancer Treatment Reviews, published by Elsevier Science Ltd, is a leading international journal dedicated to the exploration and advancement of therapeutic strategies in oncology. With an impressive impact factor that reflects its status in the field, this journal is classified within Q1 quartile rankings in Medicine (Miscellaneous), Oncology, and Radiology, Nuclear Medicine and Imaging, as of 2023. The journal has a rich lineage, having been established in 1974 and consistently evolving to encompass the latest breakthroughs and methodologies in cancer treatment. A vital resource for researchers, clinicians, and students alike, it aims to promote understanding and application of effective interventions, thereby contributing to improvements in patient outcomes. By prioritizing high-quality reviews, Cancer Treatment Reviews plays an essential role in bridging the gap between current research and clinical practice, making it an indispensable asset in the continuous fight against cancer.

Cancer Management and Research

Connecting researchers to redefine cancer care.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1322Frequency: 1 issue/year

Cancer Management and Research, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing the field of oncology. Since its inception in 2009, this journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals focused on cancer treatment and management. With its robust impact factor and impressive Scopus ranking in the 77th percentile of oncology medicine, it provides a prominent platform for sharing high-quality research. The journal covers a wide range of topics within cancer management, including innovative therapeutic strategies, clinical trials, patient care, and health policy, ensuring a comprehensive approach to current challenges in the field. Operating from New Zealand, it invites contributions that can shape the future of oncology and improve patient outcomes globally, making it an essential addition to the libraries of those engaged in cancer research and practice.

Revista Colombiana de Cancerologia

Your Gateway to the Latest in Cancer Research
Publisher: INST NACIONAL CANCEROLOGIAISSN: 0123-9015Frequency: 4 issues/year

Revista Colombiana de Cancerologia is a premier journal dedicated to advancing the field of oncology in Colombia and beyond. Published by the Instituto Nacional de Cancerología, this journal serves as a vital platform for the dissemination of high-quality research, comprehensive reviews, and innovative methodologies pertinent to cancer research and treatment. With an ISSN of 0123-9015 and E-ISSN 2346-0199, it aims to engage a diverse audience, including researchers, healthcare professionals, and students, fostering collaboration and knowledge sharing within the oncology community. Although specific metrics such as impact factors and H-index are currently unavailable, the journal is committed to maintaining high academic standards and encouraging open access to vital oncological insights. The Revista Colombiana de Cancerologia is positioned as an essential resource for those interested in the latest advancements in cancer care, prevention, and research methodologies, making significant contributions to the understanding and management of cancer.